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Abstract
Background: There is increasing interest in the identification of people at risk of rheumatoid arthritis (RA) to monitor
the emergence of early symptoms (and thus allow early therapy), offer lifestyle advice to reduce the impact of
environmental risk factors and potentially offer preventive pharmacological treatment for those at high risk. Close
biological relatives of people with RA are at an increased risk of developing RA and are therefore potential candidates
for research studies, screening initiatives and preventive interventions. To ensure the success of approaches of this kind,
a greater understanding of the perceptions of this group relating to preventive measures is needed.
Methods: Twenty-four first-degree relatives of patients with an existing diagnosis of RA from the UK, three from
Germany and seven from Austria (age: 21–67 years) took part in semi-structured interviews exploring their perceptions
of RA risk, preventive medicine and lifestyle changes to reduce RA risk. Interviews were audio-recorded, transcribed
verbatim and analysed using thematic analysis.
Results: Many first-degree relatives indicated that they anticipated being happy to make lifestyle changes such as
losing weight or changing their diet to modify their risk of developing RA. Participants further indicated that in order to
make any lifestyle changes it would be useful to know their personal risk of developing RA. Others implied they would
not contemplate making lifestyle changes, including stopping smoking, unless this would significantly reduce or eliminate
their risk of developing RA. Many first-degree relatives had more negative perceptions about taking preventive
medication to reduce their risk of RA, and listed concerns about potential side effects as one of the reasons for not
wanting to take preventive medicines. Others would be more willing to consider drug interventions although some
indicated that they would wish to wait until symptoms developed.
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Conclusions: Information targeted at those considered to be at risk of RA should contain information about RA, the
extent to which risk can be quantified at an individual level and how risk levels may differ depending on whether early
symptoms are present. The benefits (and risks) of lifestyle changes and pharmacological interventions as potential
preventive measures should be clearly described.
Keywords: Rheumatoid arthritis, Risk, Qualitative, Relatives, Preventive medicine, Lifestyle changes,
Background
Rheumatoid arthritis (RA) is a common chronic inflam-
matory disease with a prevalence of 1% [1]. The disease
has a significant negative impact at both individual and
societal levels [2]. Early diagnosis and treatment reduce
the risk of future joint damage and disability [3–8] and
increase the chance of drug-free remission [9]. As a re-
sult, there is now a drive to identify and treat people as
early in the disease process as possible, potentially before
the onset of joint swelling [10].
Genetic factors contribute significantly to a person’s risk
of developing RA [11]. Having a family history, especially
having one or more first-degree relatives with RA, increases
the risk of developing RA by approximately 3–5 fold [12–
14]. Modifiable environmental factors such as smoking
[15], alcohol intake [16, 17], and diet [18–20] also influence
the risk of developing RA [21]. Interactions between these
risk factors are likely [22]. Gathering information about an
individual’s genotype, environmental exposures, systemic
and joint related immune abnormalities may thus allow
clinicians to predict future RA development in those who
are currently asymptomatic [22]. Among those people with
a close relative with RA, current risk models using both
environmental and genetic factors have been shown to be
highly discriminative for both seropositive and seronegative
RA [23].
Relatives of RA patients are a prime target population
for both risk stratification and preventive interventions
[24, 25]. First-degree relatives of RA patients are cur-
rently in the focus of prospective observational cohort
studies [26–28] and interventional trials [21, 25]. How-
ever, difficulties recruiting first-degree relatives to such
studies have been reported [29]. As recruitment of
first-degree relatives is usually dependent on the cooper-
ation of RA patients themselves, it is also important to
understand patients’ perceptions of RA risk, risk modifi-
cation and the communication about these issues with
their relatives. Qualitative studies have already started to
explore the views of RA patients in this context [30].
In order to develop effective recruitment strategies and
potential future preventive strategies for first-degree rela-
tives we also need to have a good understanding of the
perceptions this group, and their willingness to engage
with preventive approaches. We have recently reported
data from interviews with first-degree relatives in three
European countries looking at their perceptions of being
at risk of RA and of predictive testing. Relatives reported
having a range of concerns about both predictive testing
and risk information related to RA, including the possibil-
ity that knowing ones risk might increase anxiety and re-
ported concerns about the level of uncertainty associated
with predictive testing. Those relatives who expressed
positive views about predictive testing indicated that they
would need support to understand risk information [22].
Recent qualitative research has suggested that uptake
of preventive medication by first-degree relatives might
be related to perceived baseline risk and experience of
the disease through their relative(s) [31]. Furthermore,
preliminary data from a choice experiment with
first-degree relatives suggest that acceptance of such
medication would depend on its effectiveness and side
effect profile [24]. In relation to lifestyle changes, one re-
cent trial looked at the effect of disclosure of first-degree
relatives’ RA risk personalised with genetics, biomarkers,
and lifestyle factors on their health behaviour intentions
and actual behaviour [21] and found that those at risk
were motivated to and actually changed certain behav-
iours after such personalised information. However,
there is currently no information available about
first-degree relatives’ perceptions around these lifestyle
changes and pharmacological interventions aimed at re-
ducing the risk of RA development. This paper provides
an exploration of previously unreported data collected
during our earlier interview study [22] with first-degree
relatives examining these issues in more detail.
Methods
Participants
Eligible participants were the first-degree relatives of
people with an existing diagnosis of RA. Patients with
RA were approached during their routine secondary care
clinic appointments in Birmingham (United Kingdom),
Erlangen (Germany) and Vienna (Austria) and asked to
consider contacting a first-degree relative about partici-
pation in an interview study about risk and predictive
testing for RA. Full procedural details are presented else-
where [22]. We restricted the selection of relatives to
offspring and siblings and excluded parents. In order to
be eligible to take part, first-degree relatives had to be
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aged 18 years or over and not diagnosed with inflamma-
tory arthritis at the time of the study.
Data collection and analysis
The semi-structured interviews were conducted either face
to face at the recruiting hospital sites or by telephone and
were guided by an interview schedule (Table 1). The sched-
ule was informed by a literature review [32, 33] and in con-
sultation with an international team of healthcare
professionals, researchers and patient research partners
participating in the EuroTEAM (Towards Early diagnosis
and biomarker validation in Arthritis Management) project
[34]. The interviewers in the UK were conducted by RS (fe-
male research fellow with a psychology background) and
KK (female researcher and nurse specialist)). Interviews in
Germany were conducted by AH (male senior clinical re-
search fellow) and interviews in Austria were conducted by
EM (female occupational therapist and researcher). All in-
terviewers had previous experience of conducting inter-
views and RS, KK, and EM have extensive experience of
qualitative methods. Interviewees received information
about EuroTEAM in the participant information sheet (i.e.
that it is a multi-country research project funded by the
EU) and were told the name of the person interviewing
them, as well as their role in the project. All interviews
were audio recorded and transcribed by a professional
transcription service. Interviews conducted in Germany
and Austria were translated from German into English fol-
lowing transcription by bilingual native speakers and the
translations were checked by the respective research teams.
All transcripts were analysed centrally at the University of
Birmingham, United Kingdom.
Data collection and analysis were carried out in parallel
to allow for an assessment of when thematic saturation
had been achieved. Transcripts were analysed thematically
[35] using NVivo (software programme for qualitative
data analysis; [36]). One researcher (RJS) coded all the
transcripts and three patient research partners blind coded
three transcripts. The coding framework was discussed
with the patient research partners and coding categories
that lacked concordance were absorbed into the coding
framework. The initial codes were then grouped into the
most noteworthy and frequently occurring categories by
RJS, KK and GS.
Results
Thirty-four first-degree relatives of RA patients were
interviewed; 24 from the UK, three from Germany and
seven from Austria. Participants were aged between 21
and 67 years (M = 39, SD = 10.8), and 76% (n = 26) were
female. All but two British participants were white.
Table 2 gives the individual participant characteristics in-
cluding age, gender, relation to relative with RA and
current musculoskeletal symptoms.
Interviews lasted between 30 and 90 min. The results
presented here represent a new analysis of the resulting
transcribed data. Findings related to an analysis of percep-
tions of risk and predictive testing are presented elsewhere
[22]. The core themes presented here focus on perceptions
of first-degree relatives about the possibility of making life-
style changes and taking preventive medicine to modify
their risk of developing RA. An overview of the organising
themes and subthemes can be found in Table 3. Quotations
referred to in the text can be found in Tables 4 and 5.
Modifying risk through lifestyle intervention
Many participants expressed positive views about under-
taking lifestyle changes to reduce their risk of developing
RA in the future (Table 4, Quote 1 (T4Q1)) or to delay
the start of the disease (T4Q2). The main lifestyle factors
identified by participants included healthy eating, increas-
ing levels of exercise and smoking cessation. Some partici-
pants indicated that they were already trying to live as
healthily as possible (although not necessarily focused on
preventing RA), but that they would be willing to make
additional changes (T4Q3–4). Diet in particular was
highlighted as a modifiable risk factor for development of
RA and one which patients could take control of (T4Q5).
Some participants felt that being overweight and ageing
were risk factors for the development of RA (T4Q6).
Participants felt it would be useful to know their per-
sonal risk of developing RA so they could modify their life-
style as a preventive measure (T4Q7). Many participants
indicated that they would need information about if and
Table 1 Outline Interview schedule
• Tell me what you know about RA?
• Do you ever worry about the possibility of developing RA in the
future?
• What would you think if you were told that you could have a test that
would tell you how likely you were to develop RA?
• What would your concerns be if you knew what your risk of
developing RA was?
• What kind of tests do you think people might be able to do to work
out whether or not you might develop RA (tests that are available now
and tests that might become available in the future)?
• Various tests can currently be done, and various tests are currently
being developed to predict the development of RA. What are your
thoughts about:
° Blood tests looking at biomarkers, molecules in the blood
° Blood tests looking at genes
° Tests involving scanning the joints with either an ultrasound or MRI
° Tests involving taking tissue out of a joint or elsewhere (e.g. lymph
nodes)
• What are your thoughts about taking medicines to reduce the risk of
RA developing in the future?
• What are your thoughts about changing your lifestyle (e.g. stop
smoking, more exercise, change diet) to reduce the risk of developing
RA in the future?
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how certain factors such as exercise and diet might impact
on the risk of developing RA before deciding what they
would do (T4Q8–9).
Some participants expressed more negative views and
indicated that they might not be prepared to make lifestyle
changes as a preventive measure. Some were more con-
cerned about the perceived negative consequences of
making such changes and as a result of that might not
want to engage with them (T4Q10). One person indicated
that if the only information they have, is that they are at a
heightened risk of RA they would not make a change to
their diet (T4Q11).
Only a small proportion of the first-degree relatives
were current smokers (five, one of whom smoked very
rarely) and 2 were ex-smokers. Whereas one smoker de-
scribed their willingness to give up smoking if a test result
identified him as being a person at risk (T4Q12–13), an-
other smoker indicated that a 50% baseline risk would not
Table 2 Interviewee characteristics
Participant number Gender Age Ethnicity Interview Country First degree
relative with RA
Experience of
(blood) testinga
Reported musculoskeletal
problemsa
1 Female 18–40 White UK Parent None None
2 Female 41–60 White UK Parent None Yes (Historic)
3 Male 61–80 White UK Sibling None None
4 Male 18–40 White UK Parent None None
5 Female 18–40 White UK Parent None None
6 Male 18–40 White UK Parent Yes None
7 Female 18–40 White UK Parent None Yes
8 Female 18–40 White UK Parent Yes Yes
9 Female 41–60 White UK Sibling None Yes
10 Female 18–40 White UK Parent None Yes
11 Female 41–60 White UK Sibling/Parent None Yes
12 Female 41–60 White UK Sibling None Yes
13 Female 41–60 White UK Sibling/Parent Yes Yes
14 Female 41–60 White UK Parent Yes Yes
15 Female 18–40 White UK Parent None None
16 Female 18–40 White UK Parent None None
17 Female 41–60 Asian UK Parent None None
18 Female 18–40 White UK Parent None None
19 Male 41–60 Asian UK Parent None None
20 Female 18–40 White UK Parent None None
21 Female 41–60 White UK Parent None Yes (Historic)
22 Female 18–40 White UK Sibling None None
23 Female 41–60 White UK Parent None None
24 Male 41–60 White UK Parent None None
25 Female 18–40 White Germany Parent None None
26 Female 18–40 White Germany Parent None None
27 Female 41–60 White Germany Parent None None
28 Female 18–40 White Austria Parent None None
29 Male 18–40 White Austria Parent None None
30 Female 61–80 White Austria Sibling None None
31 Female 18–40 White Austria Sibling Yes None
32 Male 18–40 White Austria Parent None None
33 Male 18–40 White Austria Parent None None
34 Female 18–40 White Austria Parent None None
aData on testing and musculoskeletal problems are based on self-reports of the interviewees as interviewers had no access to health records of the interviewees
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be enough to consider stopping (T4Q14). A third smoker
indicated that they were only prepared to give up smoking
if it was confirmed to them that this would definitely pre-
vent them from developing RA (T4Q15). Participants who
were not current smokers either identified or accepted
that smoking is a risk factor for the development of RA
and contemplated how smokers may react negatively to
risk information (T4Q16). Another participant pointed
out that it can be difficult to avoid passive smoking
(T4Q17) and hence the exposure to this risk factor.
Willingness to take preventive medicines to modify risk
When discussing the possibility of taking preventive medi-
cines if identified as being at high risk of developing RA,
many participants highlighted that they would be worried
about possible side effects of these medications (T5Q1).
They indicated that they would need to think very carefully
about the pros and cons of taking preventive medication
before making a decision (T5Q2–3). Some participants fur-
ther worried about the effect of the preventive medication
on their existing medical conditions and the potential inter-
action with current medication (T5Q4–5). Other
participants considered the long-term implications of tak-
ing medicines, and whether it would, for example, have an
impact on family planning in the future (T5Q6). The im-
munosuppressive properties of disease modifying
anti-rheumatic drugs were a particular concern for partici-
pants, especially those who had seen the side-effects of such
medicines (e.g. an increased frequency of infections) experi-
enced by their family members with RA (T5Q7).
For some participants, weighing up the side-effects
of preventive treatment, which were often described
as if they were highly likely or certain to occur,
against the relative uncertainty of developing RA in
the future, meant that they would most likely decline
to have preventive medication unless it was shown to
be highly effective (T5Q8). Many participants indi-
cated that they would not be willing to take a pre-
ventive medication based on a “probability” provided
by a predictive test and that they would need more
“definitive” evidence (T5Q9). It was felt that this type
of probability information (E.g. ‘You have a 50-50
chance to develop RA’) was too uncertain to inform a
choice about medication. Participants reported that a
preventive pharmacological therapy would be consid-
ered only if the medicine was highly effective in redu-
cing their risk (T5Q10). There were further worries
about potentially taking medication for the rest of
their lives and the potential consequences of stopping
medication (T5Q11). Participants suggested that if a
test showed that there was a 50% risk that they
would develop RA, this would not be enough for
them to accept preventive medication, though they
felt that this information might encourage them to
monitor for the onset of potential symptoms of RA.
Others suggested a relatively high predicted baseline
risk might be high enough to convince them to
accept preventive medication (e.g. one interviewee
suggested this would be a 70–80% risk that they
would develop RA; T5Q12).
In addition, several participants expressed negative
opinions about taking medicines in general, in some
cases as a result of past experiences with being pre-
scribed medication that they perceived to be unneces-
sary,-and they anticipated that this attitude would
stop them from taking medication to prevent the on-
set of RA (T5Q13–14). Others indicated that, based
on the assumption of an equal level of risk reduction,
they would rather prefer to make lifestyle changes as
opposed to taking long term medication (T5Q15) in
order to reduce their risk of developing RA.
There was also a group of participants who could
understand why preventive medicine may be pre-
scribed if they were found to be at risk of developing
RA in the future and anticipated that they would be
willing to accept such treatment (T5Q16). This was
Table 3 Overview of themes related to the sub-analysis focused
on modifying risk through lifestyle and preventive medicines
Modifying risk through lifestyle intervention
• Positive view of lifestyle changes and/or continuing to engage with
healthy living to reduce risk of developing RA
• Healthy eating, diet and exercise as examples of life style changes
• Being overweight considered a risk factor
• Knowing risk is useful as it allows you to make life style changes as
a preventive measure
• Need for more information about effectiveness in order to make a
decision about lifestyle changes
• Perceived negative consequences of making life style changes
• Unwilling to make lifestyle changes including smoking cessation,
unless it is clear that there will be a significant reduction in risk
Willingness to take preventive medicines to modify risk
• Uncertainty and worry about potential short term and long term
side effects
• Perceived need to consider pros and cons carefully
• Weighing perceived uncertainty of developing RA against perceived
certainty of side effects
• Level of likelihood of getting RA affects consideration of preventive
medicine
• Negative opinion about taking medicines in general
• Preference for making lifestyle changes over taking preventive
medication
• Recognition why medication might be used
• Preference for starting medication only when first symptoms appear
• Screening will put at risk individuals on alert for early symptoms
• Perceived effectiveness of intervention (medication or lifestyle
changes) makes a significant impact on acceptability
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especially the case for those participants who had ex-
perienced the negative impact of the illness on their
relatives (T5Q17).
Participants were supportive of the idea that predictive
testing could be useful to alert those who are at high risk to
be vigilant for the early symptoms of RA, so that treatment
could be initiated as soon as symptoms appeared (T5Q18).
Many participants suggested that they would prefer this
strategy of early intervention during the symptomatic phase
as opposed to taking a preventive medicine prior to the on-
set of symptoms (T5Q19).
Finally, for some participants the issue of engaging
with a preventive intervention depended on an expect-
ation that it would definitely be effective (T5Q20).
Table 4 Modifying risk through lifestyle changes
1 “Well, I would gather information ahead of time about this disease, so, what issues are there, what characteristics, and how can you get rid of it,
how can you prevent it so that it doesn’t break out. Well, I would be more careful about my life or my health than I have up to now.” (Participant
33; male)
2 “…..it would strike a chord with me to eat healthier and be healthier if they said I can have five years extra when I’m possibly not going to get it. I’d
rather not have RA than have it and I’d do everything in my power not to have it because it doesn’t seem that much fun.” (Participant 5; female)
3 “Well, I don’t smoke and I hope I’ve got a reasonably healthy diet. Yes, if there are changes necessary to be made, I’d be happy to make them.”
(Participant 3; male)
4 “Lifestyle changes, I’m up for any kind really, yeah. Healthy eating and exercise, although I can’t do a lot but I do try and do as much as I can.”
(Participant 13; female)
5 “How I look at it is, it’s part of… if you get it the only way that you can actually do something about it is change … what you eat, the foods you
consume and stuff like that. So I’m the only one in my family that eats organic or free range food and I drink whole milk and I eat saturated fat as
well so I avoid low fat stuff so I believe it’s to do with your diet as well. By changing your diet you can actually change the way your body functions
and what happens to it.” (Participant 14; female).
6 “I think it probably half depend on what kind of person you are, I know for my sister she was much more worried than I was only because she’s a lot
older than me and she’s overweight and she saw that as kind of, like without reading the letters I could figure she was going to get it more than me.”
(Participant 5; female)
7 “I would prefer to know about (my risk of developing RA) because then I can potentially try and manage my lifestyle better in general ..…” (Participant
24; male)
8 “So,… lifestyle changes, yeah definitely, particularly with things like exercise, because that’s something, I’m not a particularly sporty person, and I
know my dad’s been very, very sporty throughout his life and, you know, what are the risks I suppose, of that? Or whether (it is) osteoarthritis that
puts the weight on your joints or, you know, that kind of information that I wouldn’t necessarily know; that’d be the kind of thing I’d be looking to
find out.” (Participant 1; female)
9 “I think that I might behave more consciously in ways of diet or, yes generally, maybe I would try somehow to prevent that it actually happens. Well,
of course, I would have to read up on what is possible in that regard, but I think I would do that.” (Participant 31; female)
10 “Well, I wouldn’t change anything about my diet and concerning sports, as I said, that’s the question, I don’t think so, due to the fact that I think it
wouldn’t stress me, I wouldn’t change my habits in sports as in doing less or doing more, whatever, because I just think, then I would become so
careful that in the end I would just sit around and not do anything anymore or exaggerate everything. That wouldn’t be a good idea, well I can’t
really imagine that, because basically I would change little or nothing.” (Participant 28; female)
11 “If all I know that I am at a heighted risk, I don’t think I would change my diet” (Participant 28; female)
12 “Yeah, I think it would have, because after seeing what my mum can go through, when it does trigger and it kicks in, yeah, without a doubt, I think,
it brings reality home. So, yeah, I think if, I’d have probably walked out and chucked the fags in the bin there and then if, certainly if they’d come
back and said, ‘Yeah, you’re in this category,’ and I thought, certainly if it was in, probably, middle to upwards, I definitely would have. If it had been
the other way, I’d have thought, ‘Right, I need to quit,’ and worked on a couple of months’ timescale to do it.” (Participant 6; male)
13 “I’ve been smoking since I was 14. I’m 31 now, so I’m thinking, ‘Well, I’ve been smoking longer than half of my life.’ I wanna be around for my son
when he’s older, … I know smoking is – because unfortunately I am a smoker – and my mum was, like, ‘You need to pack it in, anyway, but even
more so after it had ...’ Certain things can trigger it …Yeah. I’m trying to quit smoking anyway, at the moment, so I’ve reduced the fags down to
four at the moment, so I’m working down to getting to nothing.” (Participant 6; male)
14 “Yes, that’s a very good question. Since I’m a smoker and to be honest my diet isn’t really that great, I don’t know if I’d really – if someone could
confirm to me, 100%, that if I stopped smoking and had a healthier diet I could stop myself from developing RA, then I would consider it – I would
try to stop smoking and live a healthier life.” (Participant 26; female)
15 “Regarding smoking, I mean I smoke, I wouldn’t know, well if I say I have a heightened risk and that chances are 50:50 I develop it or not, then I don’t
know whether I would consider it worth it to stop smoking.” (Participant 28; female)
16 “… ..People can be very touchy, particularly about smoking. About dietary things, people are more willing to take on board the advice about leafy
green vegetables and those kind of things, but not smoking. I think there’s a little bit of them that makes them a bit over-defensive about their choice.
They get hammered from so many different aspects; I think that it’s, like, one more person, that they don’t wanna be told from another person, that
they shouldn’t smoke, so it’s quite a delicate subject. You can, sort of, give them the facts without trying to scare them, I guess.” (Participant 1;
female)
17 “I’d be happy to change my lifestyle, if I thought it was going to have an impact on me developing the disease. But like you say, the only real strong
lifestyle – well, the only one that I’m really aware of that has a massive impact, is smoking. I don’t smoke. You can’t really help but come into contact
with people that do smoke, as much as you try and limit it, and it’s not that much now.” (Participant 10; female)
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Table 5 Modifying risk through preventive medicine
1 “For me, it would depend, if I knew for sure that the danger of my developing it within the next 5 years was very high, then I would definitely try to
find out what kind of side effects it has. Most medicine has side effects and in the long run that might not be so good”. (Participant 31; female)
2 “I would definitely want to find out more about taking the medication. I do worry about the side-effects of some of the drugs. I’d have to take that into
account as well. Mild side-effects would be fine. If it was something that affected my everyday life in a negative way now then I would have to weigh-
up the pros and cons, even if it was worthwhile in the future. I’d want to know the side-effects, or the possible side-effects. Maybe even give it a trial
run. Maybe I would just do that. Try it out and see because it affects people in different ways, doesn’t it? It’s not guaranteed that you would get all of
the side-effects.” (Participant 20; female)
3 “I do think sometimes prevention is better than a cure but when I say prevention’s better than a cure I mean sometimes you know just by looking after
yourself and things like that. Whether I could take medication for something that’s not there I’m not sure about because I would presume, I’d have to
know a bit about the medication, would it be some sort of steroid you know because some medications can affect you in other ways so I would have
to know what it was and what my effects would be before I would consider something like that.” (Participant 21; female)
4 “Side effects. I would be concerned about side effects. I know with a lot of medicines you get a lot of side effects. You’re taking the medication for one
thing and then you’ve got something else developing or something else coming out of it. And being a diabetic and suffer with diabetes, blood pressure
as well, and the digestive system. So I’m a bit worried about side effects that the medication would have.” (Participant 13; female)
5 “I don’t know really. I’d have to try it but then I’d probably read up more about it, what the side effects are, because if they’ll clash with my other
medication, because if they did then the side effects I’d probably just leave it as it is then if there’s going to be worse side - if I’m going to be feeling
worse than I already am or with the pain. And then maybe it all depends. I might just stick to the painkillers and try to avoid the pain. I really don’t
want too many side effects.” (Participant 13; female)
6 “If I had to start taking that medication would that affect me having kids.” (Participant 5; female)
7 “They’ve got side effects, because I know that my mum came off the methotrexate because I think, she’d got some – I think on the x-rays of her lungs
and that, there was some shadowing, so I think he took her off the methotrexate because of that.” (Participant 2; female)
8 “So, unless you can tell me it’s going to be a significant benefit at preventing onset of disease, again, I wouldn’t want to take any medication unless it
was going to really significantly reduce my chances of developing it. So it would depend on the sort of risk … benefit profile of the two.” (Participant
10; female)
9 “I would be disinclined to take any medicines purely based on a probability factor. I would want more definitive evidence before I’d start taking
medicines.” (Participant 4; male)
10 “I’ve got to take a medication for how long, the rest of my life? … It’s a big commitment when the odds of developing the disease is still fairly high if
I’ve got a 50% risk of still developing it, whereas if you tell me, ‘Well, actually, if you take it and based on what we can tell you about your predictability
factors, your odds of developing the disease are gonna be down to 5%,’ then I might consider it..” (Participant 10; female).
11 “But it’s the weighing up, do I want to take a medication for the rest of my life, potentially, if it’s preventative? What happens if you stop it? Again, you
need trials to go on a long, long time to tell us that, and you’re just not gonna have that data … you know, even once you’ve got your predictive
things, you’re not gonna know how long somebody has to stay on that medication to prevent it. So it’s a bit commitment for the rest of your life, to
stay on a medication.” (Participant 10; female).
12 “Okay, so I think if it’s a number, I think it’d have to be fairly high for me to wanna take a preventative tablet. So probably that’d be something I think
I’d give some thought, I guess, but I suppose 50% probably wouldn’t be high enough for me to want to …do preventative medicine, but obviously I’d
be looking out for symptoms to start, you know … medication when I developed symptoms. But, no, if it was as high as, sort of 70%, 80%, I probably
be more likely to say, Okay, let’s do the preventative.” (Participant 01; female)
13 “Nothing, I don’t like pills I don’t want to say, but I don’t think much of taking medicine, I’ve always been someone who didn’t like taking medicine, in
that case (taking medicine to reduce the risk of developing the disease) I would say no” (Participant 32; male).
14 “Just I never liked taking medication. Only if I have to I would take it. If I can get away with not taking it I will not take it. I have done it in the past.
Get away with things. I’ve been told I’ve got something, not took medicine for it. They did a lot of trying to persuade me and I said no. I was adamant
that I hadn’t got that, which I was right. So I didn’t take the medication and 12 months they said, ‘Right, okay, you’re clear.’ They kept prescribing me
the medication but I wouldn’t take it.” (Participant 13; female)
15 “I try to exercise. So, I don’t know that I could modify my lifestyle, but if it was a choice – if I had options to changing my lifestyle, and it was a choice
between that and the long-term medication, and the benefits were equal between the two, I’d go for lifestyle over a medication.” (Participant 10;
female)
16 “Yeah, I think (with) that kind of information, then, I’d be much more keen to, sort of, sort out what I needed to do to try and prevent that becoming
a problem; if I could at that point take some medication to, sort of, reduce the antibodies or you know, head it of before it became a big problem.”
(Participant 2; female, 42)
17 “Dad’s been pretty bad with it at times and fortunately, at the moment, he seems to be on a fairly even keel, which is good. So I think having seen at
first- hand, I’d be much more willing to ... And then given that, if my testing came back and said I’d had a high risk, I’d be much more willing to, sort of,
then consider medication - particularly if it was (going to be) affecting my arms - a mild tablet, and the side effects weren’t too bad.” (Participant 1;
female)
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Discussion
Given the current impetus to identify early intervention
points in the RA disease pathway, it is important to under-
stand the perspectives of those at increased risk of devel-
oping RA about possible preventive interventions. The
current study looked at one particular at risk group,
first-degree relatives, and found that many anticipated be-
ing happy to make lifestyle changes such as losing weight,
increasing exercise and changing diet to modify their risk
of developing RA. However, there was less enthusiasm
about a pharmacological approach, at either the
pre-symptomatic or the symptomatic at risk stage [9, 24].
The interviewees’ reactions to the possibility of making
lifestyle changes might be in part due to the social desir-
ability of giving such a response and it is unclear how
many would actually adopt these behaviours. One would
expect that using well trained interviewers who, with one
exception were non-Rheumatologists, went some way to
avoiding such responses. Further, the results from the trial
conducted by Sparks and colleagues [21] indicate that
first-degree relatives were both motivated to modify their
behaviour and reported making actual lifestyle changes
(e.g. increasing their fish intake; quitting smoking) espe-
cially after receiving personalised information about their
risk status and the impact of health behaviours on their
risk status. This implies that first-degree relatives might
indeed follow through on making lifestyle changes after
receiving relevant (and personalised) information. Indeed,
some interviewees in the current study indicated that they
would appreciate further information about the impact of
such behavioural changes on their risk of developing RA.
Others said that they would require definitive confirm-
ation that it would lead to a significant reduction in their
risk of developing RA before contemplating making such
changes. Interviewees were more reluctant to contemplate
making changes in their lifestyle if they considered there
to be negative effects of making such changes. Stopping
smoking can be a difficult lifestyle change to make due to
the addictive nature of tobacco [37]. In our sample, the
perceived benefits of stopping smoking in relation to RA
would make some participants more likely to consider
smoking cessation if they were found to be at risk of de-
veloping RA. Others would need more certainty that this
lifestyle change would eliminate their risk of developing
RA altogether. These findings are in line with research in
other at risk groups for chronic conditions such as dia-
betes or cardiovascular disease (CVD). In a study where
individuals were given their actual risk score for CVD,
some indicated that they had made or intended to make
lifestyle changes such as diet change or stopping smoking,
whereas others would not make those changes, for
example, because they disbelieved the risk score or down-
played their risk, or because they actively resisted making
such changes and for example ‘could not be bothered’ to
stop smoking [38]. A person’s motivation to be healthy
prior to being tested for a chronic condition, will impact
on how they perceive their risk and their willingness to
make behavioural changes once they receive their results
[32]. Further research is needed to comprehensively assess
predictors of responses to information about disease risk.
The finding that first-degree relatives were more hesi-
tant about preventive medication is in agreement with
how patients with RA in previous research felt that their
family members might react if given the option of
preventive medicine [30]. In line with findings from pre-
vious research in RA (e.g [27, 39]), potential side effects,
long-term implications of taking the medication and
possible interactions with existing conditions and medi-
cations were a major concern for many of our inter-
viewees and they indicated that they would weigh up
perceived benefits and potential harms before making a
decision about therapy. Personal experiences of RA in
family members influenced decision making about the
value of preventive medication for several interviewees.
On the one hand, those who had observed the side
effects of medications such as Disease Modifying
Anti-Rheumatic Drugs (DMARDs) experienced by their
relatives indicated that they might be more reluctant to
take the medication as a preventive measure. On the
other hand, some interviewees, who had witnessed the
negative effects of RA on their relative’s daily life, were
keen to use preventive medicine to reduce the risk of de-
veloping musculoskeletal symptoms. Acceptance of pre-
ventive medication was further associated with the issue
of certainty of future RA development. Many felt that
uncertainty around future development of RA would
discourage them from accepting medications, which they
associated with negative side effects. Some interviewees
Table 5 Modifying risk through preventive medicine (Continued)
18 “I don’t know whether, then, you’d prescribe medication type thing or whether you just leave it alone and see what happens, but be mindful that you
could have symptomatic, sort of, issues going forward. And if you had those, then you’d probably want to report it, you know, to make doctors more
aware, and maybe you’d be more mindful of perhaps your condition and be aware of changes in your body, perhaps.” (Participant 6; male)
19 “So there obviously are side effects to some of the drugs, so, I guess, unless you were probably showing symptoms, you probably wouldn’t want to go
on those sorts of things. But other things like, just, you know, for your bones or whatever, I guess there you would be more than, you know, happier to
take that sort of thing in the early stages.” (Participant 2; female)
20 “If I’m taking it I’d expect it to work for me. There’s no point in taking anything that is just not going to work for you and it’s not doing the job. Like
I’ve always said, I’m not a keen person on medication but if I’m taking it then I would have expectations for it to work.” (Participant 13; female)
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indicated that they would only consider taking medication
after the onset of symptoms, and the main value of pre-
dictive screening would be to identify the extent to which
they should be on the alert for the start of RA symptoms
– at which point they would consider therapy which is
also in line with findings from a recent focus group study
with first-degree relatives [39]. Interviewees in the current
study were further not directly asked what they perceived
their current risk of developing RA to be, but it is likely
that different levels of perceived risk might have had an
impact on their views on preventative measures. Future
research should explore this relationship further.
Interviewees in this study were not provided with
detailed information about the likely duration, frequency of
method of administration of preventive treatments. Some
of our interviewees appeared to assume that treatment to
reduce their risk of RA would involve long-term medica-
tion and associated extended risk of side effects. This could
account for negative viewpoints towards such treatment.
However the trial that is currently evaluating preventive
therapy (hydroxychloroquine) for this group (asymptom-
atic individuals) involves a 12 month course [25], which
could be considered as relatively long term treatment.
A recent discrete choice experiment looking at
first-degree relatives’ preferences related to pharmacological
interventions, suggested that method of administration
may be an important determinant of preventive treatment
acceptability [40]. In contrast a related best worst scaling
pilot study found that the efficacy and risks of treatment
were more important than method of administration in
decision making about preventive treatments [24]. Further
quantitative evidence is needed to clarify the relative
importance of treatment related and other attributes in the
choices made by at risk individuals about preventive
therapy for RA.
Collectively these findings suggest that educational ap-
proaches will be needed to support preventive strategies,
and should include information about the benefits and
risks of lifestyle changes and pharmacological interven-
tions as well as details about the nature of the intervention
itself. This supportive information should be given in the
context of personalised risk estimation with clear (and
where possible quantitative) information about the poten-
tial for risk reduction associated with such interventions
[41]. As predictive algorithms for RA continue to evolve
and improve, the interplay between genetic and environ-
mental factors could be highlighted and it is possible for
interactive tools to give people personalised information
about their risk of developing RA given their genetic
make-up and current lifestyle, demonstrating how RA risk
can be changed by making certain lifestyle changes. The
recent trial of such a tool shows a positive impact on both
intended and actual risk related behaviour change [21].
However, there remains a misalignment between public
expectations of risk assessment (e.g. being able to predict
with 100% certainty whether or not an individual will de-
velop a disease) and the realistic possibilities of predictive
models – which provide probabilistic risk estimates with
varying confidence intervals [30]. Levels of confidence in
estimates of risk or efficacy may impact on preferences for
preventive treatments [30, 40, 42], therefore informational
resources accompanying preventive interventions should
therefore also manage expectations around the accuracy
of risk information [42].
Our results further highlight the need to communicate
risk information in a way that is sensitive to the per-
sonal/family context or life situation of each individual.
One could also provide information that is specifically
tailored for different groups with varying experiences of
RA in order to provide a richer, more personalised re-
flection of their own experience. First-degree relatives
are a distinct at risk group and their views are likely to
be influenced by their personal experiences with RA. As
such, their information needs are likely to be different
from those of the general population and of other at risk
groups, such as patients with clinically suspect arthralgia
[43] or undifferentiated arthritis. In ongoing research we
are exploring the perspectives of other at risk groups
and the wider public, and predictors of perceptual vari-
ability within each of these groups.
A number of limitations need to be considered when
interpreting the findings of the current research. Firstly,
the proportion of men in the sample was relatively small.
Although this does reflect the fact that fewer men than
women develop RA [1], important viewpoints may have
been missed in the current study and future research
should aim to include a larger sample size of men. Simi-
larly, although we interviewed relatives in three different
European countries, the current sample is not ethnically
diverse and as such does not comprehensively represent
the population of each of the participating countries.
The sample size and qualitative approach used here do
not allow for comparative analysis between the three
countries and assessment of cross-cultural differences
are not possible on the basis of the current data. Future
research should therefore specifically address these
omissions in order for screening and intervention pro-
grammes to be tailored for as wide a target population
as possible and to provide related information in a way
that is gender or culturally appropriate. Further quanti-
tative evidence is needed to explore psychosocial and
cultural predictors of preference heterogeneity and the
degree to which at risk individuals trade off positive and
negative aspects of preventive interventions for RA.
Since access to first-degree relatives is usually indir-
ectly through patients with existing RA, future research
needs to extend and quantify findings of previous re-
search [30] related to if and how RA patients are likely
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to communicate with their first-degree relatives about
their increased risk of developing RA and risk reduction
options. This information will help to facilitate the de-
velopment of efficient preventive approaches and re-
cruitment of participants to preventive studies. The
current research discussed participants’ willingness to
make (hypothetical) lifestyle changes. However, although
there is consensus about some lifestyle factors which in-
fluence a person’s personal risk of developing RA (such
as smoking), more research is needed to understand the
degree of risk reduction, in the context of different gen-
etic backgrounds, associated with risk related lifestyle
changes [21]. Only when such data are available can
those at risk make informed decisions about preventive
intervention.
Conclusion
The current research gives an indication of first-degree
relatives’ perceptions of lifestyle changes and preventive
medication to reduce their risk of developing RA and the
factors associated with acceptability of such preventive
measures. It identifies factors which should be highlighted
in informational materials aimed at first-degree relatives
who are considering participating in related research stud-
ies or preventive approaches as well as highlighting factors
which warrant further investigation.
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